Acerca de Hangzhou Hotide Biotech

Nuestra misión y visión

Hangzhou Hotide Biotech Co., Ltd. es un proveedor líder de productos péptidicos de alta calidad y servicios de síntesis personalizada para instituciones farmacéuticas, biotecnológicas y de investigación académica en todo el mundo. Con plataformas tecnológicas avanzadas y estrictos sistemas de control de calidad, estamos comprometidos a ofrecer soluciones innovadoras de péptidos para acelerar el descubrimiento científico y el desarrollo de fármacos.

Nuestra Misión

Avanzar en la investigación de las ciencias biológicas a través de tecnologías de péptidos innovadoras y un servicio al cliente excepcional.

Nuestra Visión

Convertirnos en un líder reconocido mundialmente en síntesis de péptidos y campos biotecnológicos relacionados.

Tecnología avanzada

Seguro de calidad

Equipo de expertos

Categorías de productos

Explore nuestra amplia gama de productos peptídicos para sus necesidades de investigación

Productos destacados

Descubra nuestros productos peptídicos más populares para investigación y desarrollo
API-Drug Peptide BPC157 Pentadecapeptide Péptido intestinal Promueve la regeneración y la curación
Acerca de este artículo
In human gastric juice, BPC 157 is stable for more than 24 hours, and thus it has good oral bioavailability (always given alone) and beneficial effects in the entire gastrointestinal tract . This is an important distinction from the otherstandard peptides, which are functionally dependent on theaddition of carrier or are otherwiserapidly destroyed in human gastric juice.Consequently, stable BPC 157 is suggested to be a mediator of Robert’s cytoprotection, which maintains the integrity ogastrointestinal mucosa. We suggest that the contribution of BPC 157 to Robert’s cytoprotection – that is, the ability to counteract fundamental alcohol-induced gastric lesions, which Robert called cytoprotection – and the ability to counteract lesions arising from the direct injurious contact of the noxious agent with the cell represent the peripheral connection between the gut and the brain axis. Perovic reported that BPC 157 has a marked therapeutic effect pertaining to the recovery of rats with a spinal cord injury with tail paralysis (1-minute compression injury of the sacrocaudal spinal cord [S2–Co1]). Specifically, a single intraperitoneal BPC 157 administration at 10 minutes post-injury counteracts the negative effects. By contrast, the spinal cord injury and tail paralysis persist in untreated rats, assessed days, weeks, months, and a year after the injury. Of note, BPC 157 attenuates the commonly caused damage . Thereby, BPC 157 therapy results in evident functional, microscopic, and electrophysiologic recovery .
Exhibición del producto
IMG_20200609_154048
IMG_20200609_155449
IMG_20200609_161417
¿Por qué elegirnos?
Of note, in rats with spinal cord injury, there is permanent reperfusion. Once BPC 157 is administered 10 minutes post-compression injury, there is continuous protection and no spontaneous spinal cord injury-induced disturbances reappear.All spinal cord injuries immediately provoke hemorrhage, with subsequent death of neurons and oligodendrocytes. Hence, it is conceivable that early hemostasis may be beneficial and enable functional recoveryafter spinal cord contusion in rats. However, the effect exerted by BPC 157 is likely different from the simple hemostatic effect that would attenuate spinal cord injury, because BPC 157 also markedly improves thrombocyte function in rats without affecting coagulation factors. During recovery from spinal cord injury, BPC 157 also directly protects the endothelium, alleviates peripheral vascular occlusion disturbances, rapidly activates alternative bypass pathways, and counteracts venous occlusion–induced syndromes. Thus, assuming that there is a substantial venous contribution to the spinal cord compression, it is conceivable that the reestablished blood flow mediated by BPC 157 may undoubtedly contribute to the rapid recovery effect. Furthermore, considering that BPC 157 promotes permanent reperfusion after spinal cord compression, it should be noted that when BPC 157 is given during reperfusion, it counteracts stroke induced by bilateral clamping of the common carotid arteries. BPC 157 resolves neuronal damage and prevents memory, locomotor, and coordination deficits. BPC 157 apparently exerts these effects by altering gene expression in the hippocampus . In conclusion, BPC 157 exerts beneficial effects on stroke, schizophrenia, and spinal cord injury . Researchers have consistently demonstrated that BPC 157 exerts a myriad of beneficial effects throughout the body. There is no reason to indicate that the benefits of BPC 157 are limited by the validity of the utilized models and/or methodology limitations. Indeed, we can argue that the effectiveness, easy applicability, safe clinical profile and mechanism of BPC 157 represent an alternative, likely successful, future therapeutic direction for neurological conditions. Therefore, additional studies are needed to clarify how potential BPC 157 therapy would specifically deal with a mechanism of action that involves multiple subcellular sites in the CNS. The influence on the function of most, if not all, neuronal systems at the molecular, cellular, and systemic levels should be explored. Some visceral repetitive relay of the CNS or circumventricular organs, one of the few regions in the brain without the blood-brain barrier, is a known pathway by which a systemically administered peptide can exert a central effect. Thus, it must act within the gut-brain axis, regardless of whether this action is direct or indirect.
Leer más
API-Droga Péptido Pepstatina/ Pepstatina A Inhibición de pepsina, catepsina D y proteasa del VIH
Acerca de este artículo
Pepstatin is a pentapeptide, a naturally occurring aspartyl protease inhibitor, which can inhibit aspartic protease and acid protease of various microorganisms. Pepstatin is mainly secreted by Streptomyces species and produced by Streptomyces. It can inhibit pepsin, pepsin D and angiotensin-releasing enzyme, and has therapeutic effects on gastric ulcer, renal hypertension, arthritis, carrageenan edema and other diseases. Pepstatin is a strong inhibitor of aspartyl proteases such as pepsin, cathepsin D, and renin. This natural pentapeptide isolated from actinomycetes was for many years the classic renin inhibitor in vitro.Pepstatin is not specific for renin and is poorly soluble in water. Structural derivatives of pepstatin increased its solubility and specificity for renin by several orders of magnitude.Pepstatin contains the unusual γ amino acid statin that may substitute for the two amino acids at the scissile bond of the protein substrate and block substrate cleavage because of the structural analogy to a transition state of the peptide bond hydrolysis by aspartyl proteases.
Exhibición del producto
IMG_20200609_154048
IMG_20200609_155449
IMG_20200609_161417
¿Por qué elegirnos?
Cuando se extrae proteína de células rotas, se pueden liberar proteasas, que deben inhibirse rápidamente para evitar que la proteína se degrade. En el proceso de extracción de proteínas, es necesario agregar inhibidores de proteasa para prevenir la proteólisis. El inhibidor de proteasa se refiere en términos generales a una sustancia que se une a algunos grupos en el centro activo de las moléculas de proteasa, de modo que la actividad de la proteasa disminuye o incluso desaparece, pero no desnaturaliza la proteína enzimática. La sensibilidad de distintas proteasas a diferentes proteínas es diferente, por lo que es necesario ajustar la concentración de distintas proteasas. Debido a que la solubilidad del inhibidor de proteasa en líquido es extremadamente baja, se debe prestar especial atención a que el inhibidor de proteasa se mezcle completamente en el tampón para reducir la precipitación del inhibidor de proteasa. La pepstantina A puede inhibir las proteasas ácidas como la pepsina, la angiotensina, la colagenasa, la catepsina D y la quimosina.
API-Droga Peptid1
Pepstatin A is an inhibitor of cathepsin d and e. After HEK293 cells were treated with different concentrations of pepstatin A for 24 hours, the expression of LC3Ⅱ and p62 was detected. The results showed that pepstatin A could significantly enhance the expression of LC3Ⅱ and P62 (P < 0.05) in a dose-dependent manner. 20μ g/ml pepstatin A was used to treat HEK293 at different time intervals, and the effects of different time intervals on the expression of LC3II and p62 were observed. The results showed that pepstatin A could up-regulate the expression of LC3II and p62 in a time-dependent manner. We are a polypeptide manufacturer in China, with several years of mature experience in polypeptide production. Hangzhou Taijia Biotech Co., Ltd. is a professional polypeptide raw material manufacturer, which can provide tens of thousands of polypeptide raw materials and can also be customized according to needs. The quality of polypeptide products is excellent, and the purity can reach 98%, which has been recognized by users all over the world.Welcome to consult us.
Leer más
Cagrilintida: un agonista dual de AMYR/CTR para la investigación de la obesidad
Acerca de este artículo
Cagrilintida es un péptido sintético que imita la acción de la amilina, una hormona secretada por el páncreas que regula los niveles de glucosa en sangre y el apetito. Está compuesto por 38 aminoácidos y contiene un enlace disulfuro. Cagrilintida se une tanto a los receptores de amilina (AMYR) como a los receptores de calcitonina (CTR), que son receptores acoplados a proteína G expresados ​​en varios tejidos, como el cerebro, el páncreas y el hueso. Al activar estos receptores, la cagrilintida puede reducir la ingesta de alimentos, disminuir los niveles de glucosa en sangre y aumentar el gasto energético. La cagrilintida se ha investigado como un posible tratamiento para la obesidad, un trastorno metabólico caracterizado por un exceso de grasa corporal y un mayor riesgo de diabetes, enfermedades cardiovasculares y cáncer. La cagrilintida ha mostrado resultados prometedores en estudios con animales y ensayos clínicos, demostrando una pérdida de peso significativa y un mejor control glucémico en pacientes obesos con o sin diabetes tipo 2.
Exhibición del producto
IMG_20200609_154048
IMG_20200609_155449
IMG_20200609_161417
¿Por qué elegirnos?
producto1
Figura 1. Modelo de homología de cagrilintida (23) unida a AMY3R. (A) La parte N-terminal de 23 (azul) está formada por una hélice a anfipática, profundamente enterrada en el dominio TM de AMY3R, mientras que se predice que la parte C-terminal adoptará una conformación extendida que se une a la parte extracelular del receptor. (29,30) El ácido graso unido al extremo N de 23, los residuos de prolina (que minimizan la fibrilación) y la amida C-terminal (esencial para la unión al receptor) se resaltan en representaciones de barras. AMY3R está formado por CTR (gris) unido a RAMP3 (proteína 3 modificadora de la actividad del receptor; naranja). El modelo estructural se creó utilizando las siguientes estructuras de plantilla: una estructura compleja de CGRP (receptor similar al receptor de calcitonina; código pdb 6E3Y) y una estructura cristalina apo de la columna vertebral 23 (código pdb 7BG0). (B) Ampliación de 23 destacando el enlace disulfuro N-terminal, un puente salino interno entre los residuos 14 y 17, un "motivo de cremallera de leucina" y un enlace de hidrógeno interno entre los residuos 4 y 11. (adaptado de Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K. Desarrollo de cagrilintida, un análogo de amilina de acción prolongada. J Med Chem. 12 de agosto de 2021;64(15):11183-11194.)
Some of the biological applications of cagrilintide are: Cagrilintide can modulate the activity of neurons in the hypothalamus, the brain region that controls appetite and energy balance (Lutz et al., 2015, Front Endocrinol (Lausanne)). Cagrilintide can inhibit the firing of orexigenic neurons, which stimulate hunger, and activate anorexigenic neurons, which suppress hunger. For example, cagrilintide can reduce the expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP), two potent orexigenic peptides, and increase the expression of proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), two anorexigenic peptides, in the arcuate nucleus of the hypothalamus (Roth et al., 2018, Physiol Behav). Cagrilintide can also enhance the satiating effect of leptin, a hormone that signals the body’s energy status. Leptin is secreted by adipose tissue and binds to leptin receptors on hypothalamic neurons, inhibiting orexigenic neurons and activating anorexigenic neurons. Cagrilintide can increase the sensitivity of leptin receptors and potentiate leptin-induced activation of signal transducer and activator of transcription 3 (STAT3), a transcription factor that mediates leptin’s effects on gene expression (Lutz et al., 2015, Front Endocrinol (Lausanne)). These effects can reduce food intake and increase energy expenditure, leading to weight loss.
producto2
Figure 2. Food intake in rats after subcutaneous administration of Cagrilintide 23. (adapted from Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194.) Cagrilintide can regulate the secretion of insulin and glucagon, two hormones that control blood glucose levels. Cagrilintide can inhibit glucagon secretion from alpha cells in the pancreas, which prevents excessive glucose production by the liver. Glucagon is a hormone that stimulates the breakdown of glycogen and the synthesis of glucose in the liver, raising blood glucose levels. Cagrilintide can suppress glucagon secretion by binding to amylin receptors and calcitonin receptors on alpha cells, which are coupled to inhibitory G proteins that reduce cyclic adenosine monophosphate (cAMP) levels and calcium influx. Cagrilintide can also potentiate insulin secretion from beta cells in the pancreas, which enhances glucose uptake by the muscles and adipose tissue. Insulin is a hormone that promotes the storage of glucose as glycogen in the liver and muscles, and the conversion of glucose to fatty acids in adipose tissue, lowering blood glucose levels. Cagrilintide can enhance insulin secretion by binding to amylin receptors and calcitonin receptors on beta cells, which are coupled to stimulatory G proteins that increase cAMP levels and calcium influx. These effects can lower blood glucose levels and improve insulin sensitivity, which can prevent or treat type 2 diabetes (Kruse et al., 2021, J Med Chem; Dehestani et al., 2021, J Obes Metab Syndr.). Cagrilintide can also affect the function of osteoblasts and osteoclasts, two types of cells that are involved in bone formation and resorption. Osteoblasts are responsible for producing new bone matrix, while osteoclasts are responsible for breaking down old bone matrix. The balance between osteoblasts and osteoclasts determines the bone mass and strength. Cagrilintide can stimulate osteoblast differentiation and activity, which increases bone formation. Cagrilintide can bind to amylin receptors and calcitonin receptors on osteoblasts, which activate intracellular signaling pathways that promote osteoblast proliferation, survival, and matrix synthesis (Cornish et al., 1996, Biochem Biophys Res Commun. ). Cagrilintide can also increase the expression of osteocalcin, a marker of osteoblast maturation and function (Cornish et al., 1996, Biochem Biophys Res Commun.). Cagrilintide can also inhibit osteoclast differentiation and activity, which decreases bone resorption. Cagrilintide can bind to amylin receptors and calcitonin receptors on osteoclast precursors, which inhibit their fusion into mature osteoclasts (Cornish et al., 2015). Cagrilintide can also reduce the expression of tartrate-resistant acid phosphatase (TRAP), a marker of osteoclast activity and bone resorption (Cornish et al., 2015, Bonekey Rep.). These effects can improve bone mineral density and prevent or treat osteoporosis, a condition characterized by low bone mass and increased fracture risk (Kruse et al., 2021; Dehestani et al., 2021, J Obes Metab Syndr.)
Leer más
API-Drug Peptide Ziconotide/OMEGA-CGTX MVII Un bloqueador de canales de calcio tipo N
Acerca de este artículo
Es adecuado para inyección intratecal y otros métodos de tratamiento (como analgésicos sistémicos, terapia adyuvante o vaina). La ziconotida es un bloqueador de los canales de calcio sensible al voltaje de tipo N potente, selectivo y reversible, que es eficaz para el dolor refractario y no produce resistencia a los medicamentos después de una administración a largo plazo, y no causa dependencia física y mental, ni causa depresión respiratoria potencialmente mortal debido a sobredosis. La dosis diaria recomendada es menor, con buen efecto curativo, alta seguridad, menos reacciones adversas, sin resistencia a los medicamentos ni adicción. Este producto tiene una enorme perspectiva de mercado como analgésico.
Exhibición del producto
IMG_20200609_154048
IMG_20200609_155449
IMG_20200609_161417
¿Por qué elegirnos?
According to incomplete statistics, the incidence of pain in the world is about 35% ~ 45% at present, and the incidence of pain in the elderly is relatively high, about 75% ~ 90%. An American survey shows that the incidence of migraine increased from 23.6 million in 1989 to 28 million in 2001. In the investigation of chronic pain in six cities in China, it is found that the incidence of chronic pain in adults is 40%, and the rate of medical treatment is 35%; The incidence of chronic pain in the elderly is 65% ~ 80%, and the rate of seeing a doctor is 85%. In recent years, the medical expenses for pain relief are increasing year by year. From 2013 to July 2015, the Pain Research Center in the United States and several medical institutions conducted a long-term, multi-center and observational study on intrathecal injection of ziconotide in 93 adult white female patients with severe chronic pain. The pain digital score scale and the overall sensory score of patients with intrathecal injection of ziconotide and without injection of ziconotide were compared Among them, 51 patients used intrathecal injection of ziconotide, while 42 patients did not. The baseline pain scores were 7.4 and 7.9, respectively. The recommended dose of intrathecal injection of ziconotide was 0.5-2.4 mcg/ day, which was adjusted according to the patient's pain response and side effects. The average initial dose was 1.6 mcg/ day, 3.0 mcg/ day at 6 months and 2.5 at 9 months. At 12 months, it was 1.9 mcg/ day, and after 6 months, the decrease rate was 29.4%, the contrast increase rate was 6.4%, and the improvement rate of overall sensory score was 69.2% and 35.7% respectively. After 12 months, the decrease rate was 34.4% and 3.4% respectively, and the improvement rate of overall sensory score was 85.7% and 71.4% respectively. The highest side effects were nausea (19.6% and 7.1%), hallucination (9.8% and 11.9%) and dizziness (13.7% and 7.1%). The results of this study once again confirmed the effectiveness and safety of ziconotide recommended as a first-line intrathecal injection. The preliminary study on ziconotide can be traced back to the 1980s, when the potential therapeutic application of rigid and protein-like peptides in conus venom was explored for the first time. These conotoxins are small peptides rich in disulfide bonds, usually 10-40 residues in length, to target various ion channels, GPCR and transporter proteins efficiently and selectively. Ziconotide is a 25-peptide derived from Conus magus, which contains three disulfide bonds, and its short β-fold is spatially arranged into a unique three-dimensional structure, which allows it to selectively inhibit CaV2.2 channels.
Leer más
API-Drug Peptide Linaclotide: una pastilla para el alivio y la comodidad intestinal
Acerca de este artículo
Linaclotide is a cyclic peptide that consists of 14 amino acids, three of which are cysteines that form disulfide bonds. Linaclotide is structurally related to the endogenous peptides guanylin and uroguanylin, which are natural ligands of the guanylate cyclase C (GC-C) receptor. The GC-C receptor is expressed on the luminal surface of the intestinal epithelial cells, where it regulates fluid secretion and intestinal motility. Linaclotide binds to the GC-C receptor with high affinity and specificity, and activates it by increasing the intracellular levels of cyclic guanosine monophosphate (cGMP). cGMP is a second messenger that mediates various cellular responses, such as chloride and bicarbonate secretion, smooth muscle relaxation, and pain modulation. Linaclotide acts locally in the gastrointestinal tract, and does not penetrate the blood-brain barrier or affect the central nervous system. Linaclotide also produces an active metabolite, MM-419447, which has similar pharmacological properties to linaclotide. Both linaclotide and its metabolite are resistant to proteolytic degradation by intestinal enzymes, and are mainly eliminated unchanged in the feces (MacDonald et al., Drugs, 2017). By activating the GC-C receptor, linaclotide increases the secretion of fluid into the intestinal lumen, which softens the stool and facilitates bowel movements. Linaclotide also reduces the visceral hypersensitivity and inflammation that are associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders. Linaclotide modulates the activity of the enteric nervous system and the colonic nociceptors, which are sensory neurons that transmit pain signals from the gut to the brain. Linaclotide decreases the expression of pain-related genes, such as substance P and calcitonin gene-related peptide (CGRP), and increases the expression of opioid receptors, which mediate analgesia. Linaclotide also reduces the release of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), and increases the release of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor beta (TGF-β). These effects of linaclotide improve the symptoms of constipation and abdominal pain in patients with IBS or chronic constipation (Lembo et al., The American Journal of Gastroenterology, 2018). Linaclotide has been shown to be effective and well-tolerated in several clinical trials involving patients with CC or IBS-C. In these trials, linaclotide improved bowel habits, such as stool frequency, consistency, and completeness; reduced abdominal pain and discomfort; and enhanced quality of life and patient satisfaction. Linaclotide also demonstrated a favorable safety profile, with diarrhea being the most common adverse event. The incidence of diarrhea was dose-dependent and usually mild to moderate in severity. Other adverse events were generally similar to placebo or low in frequency. No serious adverse events or deaths were attributed to linaclotide treatment (Rao et al., Clinical Gastroenterology and Hepatology, 2015).
Exhibición del producto
muestra (2)
muestra (3)
muestra (1)
¿Por qué elegirnos?
La linaclotida es un medicamento novedoso y eficaz para pacientes con CC y SII-C que no han respondido bien a las terapias convencionales. Actúa imitando la acción de los péptidos endógenos que regulan la función y la sensación intestinal. La linaclotida puede mejorar los hábitos intestinales, reducir el dolor abdominal y mejorar la calidad de vida de estos pacientes.
productos
Figure 1. Abdominal pain/abdominal discomfort and IBS degree of relief weekly responders over the 12-week.  , placebo; , linaclotide 290 μg. (Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., and Lim, S. (2018) Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. Journal of Gastroenterology and Hepatology, 33: 980–989. doi: 10.1111/jgh.14086.) We are a polypeptide manufacturer in China, with several years of mature experience in polypeptide production. Hangzhou Taijia Biotech Co., Ltd. is a professional polypeptide raw material manufacturer, which can provide tens of thousands of polypeptide raw materials and can also be customized according to needs. The quality of polypeptide products is excellent, and the purity can reach 98%, which has been recognized by users all over the world.Welcome to consult us.
Leer más
Mazdutide 2259884-03-0
Leer más
Retatrutida/2381089-83-2
Leer más
Medicamento API/Tirzepatida/USDMF/GMP
Leer más
API fármaco semaglutida, péptido API

CAS No.: 910463-68-2

Fórmula molecular: C187H291N45O59
Peso molecular: 4113,64
Secuencia: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(17-carboxi-1-oxoheptadecil-L-γ-glutamil[2-(2-aminoetoxi)etoxi] acetil[2-(2-aminoetoxi)etoxi]acetil]-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Aplicación: Análogo del péptido 1 similar al glucagón humano (GLP-1) de acción prolongada utilizado para el tratamiento de la diabetes.

Leer más
Survodutida/CAS:2805997-46-8
Leer más
Péptido cosmético acetil hexapéptido -8/Argireline Materias primas cosméticas de alta actividad antiarrugas
Acerca de este artículo
Acetyl hexapeptide -8, also known as akirelin and hexapeptide. Acetyl hexapeptide -8 is also called "botulinum toxin-like"/"smear botulinum toxin" by many people. It can be said that aquiline is an anti-wrinkle polypeptide with better effect than botulinum toxin.
Exhibición del producto
IMG_20200609_154048
IMG_20200609_155449
IMG_20200609_161417
¿Por qué elegirnos?
As we all know, botulinum toxin is a beauty product that needs injection. It is extremely dangerous to use, and needs to be used by professionals. The dosage should be strictly controlled, but it still cannot avoid various side effects such as facial stiffness and facial paralysis. Argireline was verified in the human experiments of cosmetics manufacturers: the average wrinkle depth decreased by 16.9% and 27.0% after 15 and 30 days with 10% Argireline solution, and the wrinkle volume decreased by 20.6% and the wrinkle length decreased by 15.9% after only 7 days with 2% Argireline solution. It can be seen that the effect of achillerin on wrinkles is very significant.
muestra1
Wrinkles in human facial skin are mostly caused by collagen relaxation and involuntary contraction of muscles. If the contraction of these muscles can be controlled, the skin muscles can be relaxed to relieve wrinkles and achieve the fundamental purpose of removing wrinkles. Botulinum toxin, as an effective wrinkle removal method, is widely known for its excellent effect. Even if it will cause great risks after use, there will still be a large number of consumers willing to use it. Polypeptide is different. As an organic synthetic product, when used as a cosmetic ingredient, it can be rapidly degraded into free amino acids at low concentration. Its main sequence is based on human body and its mechanism of action is natural. The characteristics of small molecular peptides enable them to have good transdermal permeability and are well absorbed by the human body. Acetyl hexapeptide -8 prevents nerve from transmitting muscle contraction information through the mechanism similar to botulinum toxin, so that muscle cannot contract to eliminate wrinkles. It has high anti-wrinkle activity and few side effects, and has been widely used in various high-end cosmetics.
muestra2
Somos un fabricante de polipéptidos en China, con varios años de experiencia madura en la producción de polipéptidos. Hangzhou Taijia Biotech Co., Ltd. es un fabricante profesional de materias primas de polipéptidos, que puede proporcionar decenas de miles de materias primas de polipéptidos y también se puede personalizar según las necesidades. La calidad de los productos polipeptídicos es excelente y la pureza puede alcanzar el 98%, lo que ha sido reconocido por usuarios de todo el mundo. Bienvenido a consultarnos.
Leer más
Péptido cosmético de cobre GHK-CU, 9030-95-5, tripéptido-cobre, 130120-57-9 (2:1)/1227510-36-2Tripéptido-1
Leer más

Capacidades de investigación avanzadas

Hangzhou Hotide cuenta con instalaciones de investigación de vanguardia y un equipo de científicos experimentados dedicados a la innovación en péptidos.

Síntesis de péptidos en fase sólida

Tecnología SPPS de última generación para producir péptidos de alta calidad de hasta 150 aminoácidos

Síntesis en fase de solución

Síntesis personalizada de péptidos complejos que requieren metodologías en fase de solución.

Modificación de péptidos

Experiencia en diversas modificaciones de péptidos, incluida la glicosilación, la PEGilación y la ciclación.

Pruebas analíticas

Caracterización integral de péptidos mediante HPLC, MS, NMR y otras técnicas avanzadas.

¿Por qué elegiste
nuestra empresa

En la actualidad, podemos proporcionar: glicopéptidos, péptidos marcados con isótopos, péptidos quelantes macrocíclicos, péptidos antigénicos complejos MAPS, que se utilizan en diversas investigaciones científicas; Se aplican todo tipo de péptidos marcados con fluorescencia para la determinación de la actividad enzimática y el estudio de sondas moleculares; Haga clic en el péptido químico, el péptido modificado con polietilenglicol, el péptido cíclico y el péptido de penetración celular, que se aplican a la investigación de diversos fármacos polipeptídicos para mejorar la vida media y la actividad de los fármacos polipeptídicos.

Leer más

Últimas noticias y actualizaciones

Manténgase informado sobre nuestros últimos desarrollos, avances en investigación y noticias de la industria.

Contáctenos

¿Tiene preguntas o necesita ayuda? Nuestro equipo está listo para ayudarlo con sus requisitos de péptidos.

Envíanos un mensaje

Información del contacto

DIRECCIÓN

Distrito de Qiantang, ciudad de Hangzhou, provincia de Zhejiang, China

Correo electrónico

info@hangzhouhotide.com

Horas

Lunes a viernes: 9 a.m. a 6 p.m.

Saturday, Sunday: Closed

Copyright © 2025 Hangzhou Hotide Biotech Co., Ltd. Todos los derechos reservados.

Contáctenos

Solicitar consulta